Spots Global Cancer Trial Database for Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
Official Title: A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma
Study ID: NCT00102752
Study Description
Brief Summary: The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
Detailed Description: This study, TH-CR-301, is a Phase 1/2 study that will evaluate the efficacy and safety of glufosfamide in combination with gemcitabine in advanced solid tumors or in first line treatment of pancreatic cancer. Study Hypothesis: Glufosfamide in combination with gemcitabine may provide benefits in survival to patients with advanced solid tumors or metastatic pancreatic cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona Cancer Center, Tucson, Arizona, United States
Indiana Cancer Center, Indianapolis, Indiana, United States
Norton Healthcare Cancer Center, Louisville, Kentucky, United States
Hospital de Doenças Cardiovasculares - Biocor, Nova Lima, BH, Brazil
Hospital Mãe de Deus, Porto Alegre, RS, Brazil
Hospital Nossa Senhora da Conceição, Porto Alegre, RS, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, SP, Brazil
Universidade Federal de São Paulo - Hospital São Paulo, São Paulo, SP, Brazil
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
